Cereno Scientific
5.62 SEK +13.54%2 investors are following this company
Cereno Scientific is active in biotechnology. The company specializes in drug development for common and rare cardiovascular diseases. The main drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension (PAH), as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. The head office is in Mölndal with offices also in North America.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CRNO B
Daily low / high price
5.02 / 5.74
SEK
Market cap
1.58B SEK
Turnover
17.18M SEK
Volume
3.2M
Latest videos
Financial calendar
Interim report
2024-08-29
Interim report
2024-11-21
Annual report
2025-02-25
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 20.6 % | 20.1 % |
Pareto Securities AS | 3.2 % | 3.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Cereno Scientifics styrelse och ledning ingår lock-up-avtal
Första deltagaren doserad i Cereno Scientifics first-in-human Fas I-studie av den nya HDAC-hämmaren CS014
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools